Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, United States; Oregon State University College of Pharmacy, 2730 SW Moody Ave., CL5CP, Portland, OR 97201, United States.
HealthInsight Oregon, 2020 SW 4th Avenue, Suite 520, Portland, OR 97201, United States.
Addict Behav. 2018 Nov;86:32-39. doi: 10.1016/j.addbeh.2018.04.020. Epub 2018 May 1.
Oregon's Medicaid program is delivered through 16 Coordinated Care Organizations (CCOs) participating in a statewide performance improvement program to reduce high-dose opioid prescribing. CCOs were allowed flexibility to develop their own dose targets and any policies, trainings, guidelines, and/or materials to meet these targets. In this study, we characterize CCO strategies to reduce high-dose opioid prescribing across the 16 CCOs.
We reviewed relevant CCO documents and conducted semi-structured interviews with CCO administrators to acquire opioid-related policies, practices, timelines and contextual factors. We applied a systematic coding procedure to develop a comprehensive description of each CCO's strategy. We used administrative data from the state to summarize contextual utilization data for each CCO.
Most CCOs selected a target daily morphine milligram equivalent (MME) dose of 90 mg. Sixteen issued quantity limits related to dose, eight restricted specific drug formulations (short-acting or long-acting), and 11 allowed for time-limited taper plan periods for patients over threshold. Many CCOs also employed provider trainings, feedback reports, and/or onsite technical assistance. Other innovations included incentive measures, electronic health record alerts, and toolkits with materials on local alternative therapy resources and strategies for patient communication. CCOs leveraging collaborations with regional partners appeared to mount a greater intensity of interventions than independently operating CCOs.
CCOs developed a diversity of interventions to confront high-risk opioid prescribing within their organization. As healthcare systems mount interventions to reduce risky opioid prescribing, it is critical to carefully describe these activities and examine their impact on process and health outcomes.
俄勒冈州的医疗补助计划通过 16 个参与全州绩效改进计划的协同护理组织 (CCO) 提供,旨在减少高剂量阿片类药物的处方。CCO 被允许灵活制定自己的剂量目标和任何政策、培训、指南和/或材料来实现这些目标。在这项研究中,我们描述了 16 个 CCO 降低高剂量阿片类药物处方的策略。
我们审查了相关的 CCO 文件,并对 CCO 管理人员进行了半结构化访谈,以获取与阿片类药物相关的政策、实践、时间表和背景因素。我们采用了系统的编码程序来全面描述每个 CCO 的策略。我们使用来自该州的行政数据来总结每个 CCO 的背景利用数据。
大多数 CCO 选择了 90mg 的每日吗啡毫克当量 (MME) 剂量目标。16 个 CCO 发布了与剂量相关的数量限制,8 个限制了特定的药物制剂 (短效或长效),11 个 CCO 允许超过阈值的患者进行有限时间的减量计划。许多 CCO 还提供了提供者培训、反馈报告和/或现场技术援助。其他创新包括激励措施、电子健康记录警报以及包含当地替代治疗资源和患者沟通策略的工具包。与区域合作伙伴合作的 CCO 似乎比独立运营的 CCO 开展了更多的干预措施。
CCO 制定了各种干预措施来解决其组织内的高风险阿片类药物处方问题。随着医疗保健系统采取干预措施来减少风险阿片类药物的处方,仔细描述这些活动并检查其对流程和健康结果的影响至关重要。